GlassScriptPhysician profile
Richard Kootman
NPI 1700896149
$5,755.76
in general payments reported to CMS, 2019-2025
22 companies · $610 in 2025
The $610 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,611 · 2020: $349 · 2021: $362 · 2022: $825 · 2023: $582 · 2024: $416 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,441.32 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $626.48 | 2019-2022 | |
| Rxsight INC | $471.65 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Alcon Vision LLC | $415.99 | 2021-2025 | Clareon Panoptix Pro, Clareon, Unity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $406.88 | 2019 | |
| Kala Pharmaceuticals, INC. | $341.87 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $335.08 | 2022-2024 | Miebo, Xiidra |
| Dompe US, INC. | $312.32 | 2019-2025 | Oxervate |
| Allergan, INC. | $205.24 | 2019-2020 | |
| Oyster Point Pharma, INC. | $195.17 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $181.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $140.01 | 2019-2022 | |
| Glaukos Corporation | $138.13 | 2025 | Idosetr, Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $127.37 | 2022 | |
| Shire North American Group INC | $122.03 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $102.03 | 2019 | |
| Genentech USA, INC. | $81.04 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $26.56 | 2025 | Xdemvy |
| Novo Nordisk INC | $23.21 | 2025 | Ozempic |
| Amgen INC. | $22.96 | 2022 | |
| Abbvie INC. | $22.44 | 2024 | |
| Medtronic, INC. | $16.16 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kootman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.